Kidney function is crucial for the management of patients with heart disease because even mild to moderate kidney dysfunction affects cardiovascular morbidity and mortality. Atrial fibrillation (AF) is more likely to develop in patients with advanced age, hypertension, or structural heart disease, which also precipitates kidney dysfunction. AF and kidney dysfunction often coexist in an individual patient; however, less is known about the association between AF and kidney function. We assessed changes in estimated glomerular filtration rate (eGFR) over 1 year after catheter ablation of AF. At baseline, 26% and 66% of patients had eGFR of 30 to 59 and 60 to 89 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 , respectively. During follow-up, 72% of patients were free from tachyarrhythmias after the ablation, 13% of whom were taking antiarrhythmics. Over a 1-year follow-up, patients who were free from tachyarrhythmias after ablation showed a significant increase in eGFR, whereas patients with recurrent arrhythmias showed a significant decrease in eGFR. After adjustment for age, type of AF, baseline eGFR, and baseline left ventricular ejection fraction, multivariate analysis demonstrated that freedom from tachyarrhythmia after ablation was associated with an increase in eGFR over 1 year after ablation. This study demonstrated a link between AF and kidney dysfunction. Further investigation is required to clarify the causal relationship between these 2 diseases. See p 2380.
Randomized Trial of Cutting Balloon Compared With High-Pressure Angioplasty for the Treatment of Resistant Pulmonary Artery Stenosis
Children born with congenital heart disease not uncommonly require cardiac catheterization to treat congenital and acquired malformations such as pulmonary artery stenosis, replacing or complementing surgical techniques. In this study of Cutting Balloons compared with high-pressure balloon angioplasty for resistant pulmonary artery stenosis, we have shown superior efficacy with the Cutting Balloon technology and an equivalent safety profile. This finding has important clinical application for a population with previously untreatable disease. Although few studies have evaluated the performance of devices developed for adults but used in children, in this study, we have demonstrated that some of the unique study design and execution difficulties met in the pediatric population can be overcome. We hope that future studies will continue to rigorously evaluate the performance of devices used to treat children with rare diseases relative to more common adult indications. See p 2388.
Frailty Is Independently Associated With Short-Term Outcomes for Elderly Patients With Non-ST-Segment Elevation Myocardial Infarction
There is sometimes a disconnect between biological and chronological age, and this has been identified as a major obstacle in applying evidence-based treatments. For the large and growing population of elderly patients with cardiovascular disease, it is important to identify clinically relevant measures of biological age and their contribution to risk. Frailty is an emerging concept in medicine denoting increased vulnerability and decreased physiological reserves. Frailty instruments have thus far been validated and used mainly in a geriatric context, in which frailty stratification has been shown to be associated with a patient's risk of death and need for institutional care. We analyzed the manner in which the variable frailty is associated with short-term outcomes for elderly non-STsegment elevation myocardial infarction patients. Frailty is strongly and independently associated with risk for in-hospital mortality, 1-month mortality, prolonged hospital care, and the primary composite outcome (all-cause death, myocardial reinfarction, revascularization due to ischemia, hospitalization for any cause, major bleeding, stroke/transient ischemic attack, and need for dialysis up to 1 month after inclusion). The combined use of frailty and comorbidity may constitute an ultimate risk prediction concept for cardiovascular patients with complex needs. In clinical decision making, frailty could function as a tool in estimating the patient's benefit-risk ratio associated with a treatment, including the expected lifetime for individual patients and its relation to the overall yield of a treatment. It could enhance decision making in regard to whether to focus on prognostic or symptomatic treatment. See p 2397.
Statin Use in Outpatients With Obstructive Coronary Artery Disease
In the large, contemporary Practice Innovation and Clinical Excellence (PINNACLE) outpatient registry, we examined rates of guideline-based treatment with lipid-lowering therapy in 38 775 patients with obstructive coronary artery disease (defined as history of myocardial infarction or prior coronary revascularization) and without contraindications to statin therapy. We found that 78% of patients were receiving guideline-based treatment with statins, 5% were treated only with nonstatin lipid-lowering medications, and 17% of patients were not treated with any lipid-lowering therapy at all. Among untreated patients, half had low-density lipoprotein cholesterol (LDL-C) levels Ն100 mg/dL. Despite multiple clinical trials that have shown that statin therapy reduces cardiovascular morbidity and mortality in this population, a substantial number of high-risk patients remained untreated with statins despite elevated levels of LDL-C. We also found that half of untreated patients had LDL-C levels Ͻ100 mg/dL. Although appearing to have reached established LDL-C treatment "targets" for secondary prevention, these patients were not receiving guideline-based care because they were not treated with any lipid-lowering therapy. Our data suggest that some physicians may be making decisions about lipid management for these patients on the basis of baseline LDL-C levels alone rather than on the basis of clinical trial evidence, which has demonstrated a consistent benefit with statin therapy in secondary prevention regardless of baseline LDL-C levels. These findings highlight important opportunities to improve the use of statin therapy in outpatients at high risk for recurrent cardiovascular events. See p 2405.
Distinct Epigenomic Features in End-Stage Failing Human Hearts
Molecular research in heart failure points to the hypothesis that a generic cardiac genomic response is activated in the failing myocardium regardless of the original inciting cause. This cardiac genomic stress response is typified by the re-expression of fetal genes, upregulation of fibrosis-related genes, and others. It may also reflect unifying features of a failed myocardium such as fibrosis, altered energy use, vascular rarefaction, cell death, and altered contractility, all of which are features found in the failing myocardium again regardless of the inciting cause. The epigenome refers to "marks" on the genome, including DNA methylation and histone modification.
The epigenome regulates the expression of underlying genes, and recent evidence suggests that part of the epigenome may be altered by diet and the environment. In our research, we have examined the genome-wide landscape of the epigenome of healthy and end-stage cardiomyopathic human hearts. We have determined that distinct epigenomic patterns exist in important DNA elements of the human cardiac genome in the failing myocardium. Individually, sites of differential epigenomic patterns may control the expression of specific genes with critical functions in the progression of heart failure. However whether the altered epigenome is simply a consequence in end-stage disease or actually contributes to disease progression remains to be determined. This work now opens an important new avenue of research because the epigenome may represent a drug discovery target for novel heart failure therapy. See p 2411.
Performance of the Traditional Age, Sex, and Angina Typicality-Based Approach for Estimating Pretest Probability of Angiographically Significant Coronary Artery Disease in Patients Undergoing Coronary Computed Tomographic Angiography: Results From the Multinational Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry (CONFIRM)
During the initial evaluation of a patient with chest pain, many clinicians use the age, sex, and angina typicality-based pretest probabilities currently cited in professional society practice guidelines (guideline probabilities) to direct decisions for subsequent diagnostic testing and treatment. However, guideline probabilities were derived from patients clinically referred to invasive angiography and have not been validated in patients undergoing noninvasive testing. In this multinational study, the investigators analyzed the performance of guideline probabilities in 14 048 consecutive patients, including 8106 patients with chest pain, referred for coronary computed tomographic angiography. Computed tomographic angiography was used to determine the presence of angiographically significant coronary artery disease. In patients with chest pain, guideline probabilities significantly overestimated the overall prevalence of Ն50% diameter stenotic coronary artery disease (51% versus 18% observed by computed tomographic angiography) and Ն70% diameter stenotic coronary artery disease (42% versus 10%). Overestimation was particularly pronounced in patients with atypical angina and typical angina across all sex, age, and risk factor subgroups. The large differences between observed and predicted disease prevalence persisted in sensitivity analyses adjusted for potential inaccuracies of coronary computed tomographic angiography. Results from this study illustrate a major limitation in the practice of applying disease prevalence derived from invasive coronary angiography to populations undergoing initial noninvasive evaluation for coronary artery disease and highlight the need for updating probabilities of angiographically significant coronary artery disease in such populations. See p 2423.
Identification of a Danger-Associated Peptide From Apolipoprotein B100 (ApoBDS-1) That Triggers Innate Proatherogenic Responses
Accumulated low-density lipoprotein particles in arterial wall are the primary cause of atherosclerosis by triggering chronic vascular inflammation, characterized by local activation of cellular inflammatory responses including lesional macrophages. The molecular identities of low-density lipoprotein-derived inflammatory components have been poorly defined. Apolipoprotein B100 (ApoB100) is the only unchangeable protein constituent of the low-density lipoprotein particle. Both clinical and preclinical studies suggest that ApoB100 protein fragments are implicated in modulation of immune responses in the process of disease development, implying that ApoB100 is not a bystander to the inflammation of atherosclerosis. In the present study, by screening a peptide library of human ApoB100, we have identified a previously unrecognized native peptide fragment that exhibits distinctive activity triggering inflammatory responses of human monocytes/macrophages and atherosclerotic plaques ex vivo. Given its capacity to induce innate immune responses, we named the peptide ApoB100 danger-associated signal 1, signifying the first identified ApoB100 -derived dangerassociated signal. Importantly, the peptides with specific ApoB100 danger-associated signal 1 activity are present in atherosclerosis. These findings shed light on the pathobiological role of low-density lipoprotein in atherosclerosis. See p 2433.
